Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Shengping Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2698-2757; OpenAlex author ID A5100732815. Sources: OpenAlex.

Their work

Papers
44 (first author 0, last author 30)
Trials
0
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 6 papers · 2020: 11 papers · 2021: 6 papers · 2022: 5 papers · 2023: 6 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 44

  1. Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy. Co-author DOI 10.1002/mco2.70870↗
  2. Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression. Co-author DOI 10.3389/fimmu.2026.1793161↗
  3. Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study. Last author DOI 10.2147/jir.s519779↗
  4. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Last author DOI 10.1016/j.canlet.2024.216697↗
  5. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.12.008↗
  6. Blockades Adenosine Receptor 2B Suppresses Pancreatic Adenocarcinoma Progression by Inhibiting Leukemia Inhibitory Factor Secretion from Macrophages Last author DOI 10.21203/rs.3.rs-4829619/v1↗
  7. A Cyclodiaryliodonium NOX Inhibitor for the Treatment of Pancreatic Cancer via Enzyme-Activatable Targeted Delivery by Sulfated Glycosaminoglycan Derivatives. Co-author DOI 10.1002/adhm.202203011↗
  8. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and networ… Co-author DOI 10.1007/s00228-022-03441-9↗
  9. Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery. Last author DOI 10.1007/s00432-023-04703-4↗
  10. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Co-author DOI 10.1177/17588359231186029↗
  11. Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. Last author DOI 10.2147/jir.s404900↗
  12. Establishment and validation of a prognostic signature for pancreatic ductal adenocarcinoma based on lactate metabolism-related genes. Last author DOI 10.3389/fmolb.2023.1143073↗
  13. The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2021.11.036↗
  14. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma. Last author DOI 10.1186/s12967-022-03473-w↗
  15. Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fcell.2022.839893↗
  16. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer. Last author DOI 10.3389/fmolb.2022.876607↗
  17. Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes. Co-author DOI 10.3390/ijms23094792↗
  18. LINC00460 promotes pancreatic cancer progression by sponging miR-491-5p. Last author DOI 10.1002/jgm.3333↗
  19. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Last author DOI 10.1016/j.canlet.2020.12.018↗
  20. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2021.01.014↗
  21. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. Last author DOI 10.1080/2162402x.2021.1897295↗
  22. Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irrever… Last author DOI 10.2147/jir.s307884↗
  23. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. Last author DOI 10.2147/jir.s331023↗
  24. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs… Last author DOI 10.1002/cam4.3119↗
  25. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Last author DOI 10.1002/ctm2.39↗
  26. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.41↗
  27. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.bbrc.2020.02.042↗
  28. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score ma… Last author DOI 10.1016/j.pan.2020.02.009↗
  29. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.00006↗
  30. Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessmen… Last author DOI 10.3389/fonc.2020.00590↗
  31. A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After … Last author DOI 10.3389/fonc.2020.00952↗
  32. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Last author DOI 10.3389/fonc.2020.01482↗
  33. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. Last author DOI 10.3389/fonc.2020.01564↗
  34. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.622318↗
  35. A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2526↗
  36. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  37. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  38. Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. Last author DOI 10.1155/2019/9346017↗
  39. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity sco… Last author DOI 10.1186/s12885-019-5607-3↗
  40. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Last author DOI 10.3389/fonc.2019.01197↗
  41. Intravoxel incoherent motion magnetic resonance imaging for differentiating metastatic and non-metastatic lymph nodes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-017-5259-0↗
  42. A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Last author DOI 10.7150/jca.26187↗
  43. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  44. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chaobin He · 24 shared papers, 2018–2026 · strength 3.48
  2. Xin Huang · 14 shared papers, 2018–2024 · strength 2.00
  3. Shuxin Sun · 14 shared papers, 2019–2024 · strength 1.94
  4. Xiaojun Lin · 11 shared papers, 2019–2021 · strength 1.52
  5. Dailei Qin · 6 shared papers, 2022–2025 · strength 1.28
  6. Zehui Yao · 5 shared papers, 2023–2026 · strength 1.21
  7. Yize Mao · 9 shared papers, 2018–2026 · strength 1.20
  8. Pu Xi · 4 shared papers, 2023–2026 · strength 1.02
  9. Ran Wei · 4 shared papers, 2022–2025 · strength 0.85
  10. Lingmin Jiang · 3 shared papers, 2024–2026 · strength 0.83
  11. Fengxiao Xie · 5 shared papers, 2020–2024 · strength 0.76
  12. Xujia Li · 3 shared papers, 2023–2024 · strength 0.59
  13. Guifang Guo · 3 shared papers, 2023–2024 · strength 0.59
  14. Wuguo Deng · 3 shared papers, 2021–2022 · strength 0.51
  15. Jun Wang · 4 shared papers, 2018–2024 · strength 0.48
  16. Qiuxia Yang · 3 shared papers, 2019–2023 · strength 0.44
  17. Yunda Song · 4 shared papers, 2018–2021 · strength 0.42
  18. Feng‐Hua Wang · 2 shared papers, 2023–2024 · strength 0.40
  19. Jinsheng Huang · 2 shared papers, 2023 · strength 0.40
  20. Qi Quan · 2 shared papers, 2023–2024 · strength 0.39
  21. Honglu Ding · 2 shared papers, 2023 · strength 0.39
  22. Jun Cheng · 2 shared papers, 2022–2026 · strength 0.37
  23. Guangmei Yan · 2 shared papers, 2021–2024 · strength 0.29
  24. Jing Cai · 2 shared papers, 2021–2024 · strength 0.29
  25. Liqin Li · 2 shared papers, 2022 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.